Financial PositionThe company reported cash and cash equivalents of $996M, which is believed to be sufficient to run operations for the foreseeable future.
Partnerships And CollaborationsRecent progress advancing their earlier-stage and partnered programs, including first-patient-in by collaboration partner Merck’s first masked TCE program.
Product DevelopmentJanux plans to combine the new PSMA-TRACIr program with CD3 targeting JANX007, which is believed to keep them competitive and enhance the durability of JANX007.